Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Instagram Outage Disrupts Thousands of U.S. Users 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
MALVERN, Pa., Oct. 30, 2017 -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2017 earnings on Tuesday, November 7th at 4:00 PM Eastern Time.
The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, November 7, 2017. The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com. If you are unable to participate during the live webcast, an archive will be available on our website for two weeks.
About BioTelemetry
BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The Company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services. More information can be found at www.gobio.com.
Contact:
BioTelemetry, Inc.
Heather C. Getz
Investor Relations
800-908-7103
[email protected]
